Drug intelligence / Profile preview

tucidinostat + etoposide

Development stage: Unknown
Lead developer: Akeso
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of tucidinostat, a novel, orally active benzamide class HDAC inhibitor that selectively targets HDAC1, HDAC2, HDAC3, and HDAC10, and etoposide, a chemotherapeutic agent commonly used in various cancer treatments. This combination has shown synergistic effects in vitro and additive effects in vivo, and is being investigated for various cancer indications including NK/T-cell lymphoma, neuroblastoma, and neuroendocrine tumors/carcinomas.

Brand names: Epidaza
Other names: chidamideHBI-8000HBI8000HBI 8000

Targets

HDAC11 (Histone Deacetylase 11)TOP2A (DNA topoisomerase II)HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)HDAC8 (Histone Deacetylase 8)TOP2B (DNA topoisomerase II beta)

Beyond the preview

Go deeper on tucidinostat + etoposide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tucidinostat + etoposide.

Explore the full profile